TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02522143

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Informational sessions describing BPD characteristics
Description: Control intervention consists of informational sessions describing BPD characteristics/ treatment and time- / stress-management skills

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Condensed-DBT treatment intervention
Description: The Intervention consists of an 8-week manual based psychoeducational group utilizing modified condensed-DBT Treatment manual previously used in a treatment study (Moen et al, 2012).
Study: NCT02521662

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: A transdermal patch that slowly releases nicotine into the body through the skin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: A transdermal patch that slowly releases nicotine into the body through the skin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: A transdermal patch that slowly releases nicotine into the body through the skin.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: e-cigarette
Description: A electronically powered device that delivers to the user an aerosol of propylene glycol and/or glycerine, with or without flavourings and nicotine.
Study: NCT04551274

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Music Therapy interventions involve the use of live music (performed or created by the therapist and/or patient), and a process that includes patient-specific assessment, treatment, and evaluation
Study: NCT05938764

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MICRA
Description: see earlier description

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: see earlier description
Study: NCT03324555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIC-101
Description: Oral suspension
Study: NCT02521662

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: e-cigarette
Description: A electronically powered device that delivers to the user an aerosol of propylene glycol and/or glycerine, with or without flavourings and nicotine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Nicotine contained in e-liquid (e-juice) used in e-cigarettes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioural support
Description: Withdrawal-oriented behavioural support

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioural support
Description: Withdrawal-oriented behavioural support

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioural support
Description: Withdrawal-oriented behavioural support
Study: NCT02679040

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate mammary reconstruction
Description: Chemotherapy administration then radiotherapy and then surgery : mastectomy and immediate mammary reconstruction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy treatment

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation therapy
Study: NCT01058304

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Physical Therapy for Knee OA
Description: The group PT arm will include 6 1 to 1 hour visits (every other week) led by a physical therapist and exercise physiologist or PT Assistant, with 8 participants per group. The group PT sessions will include group instruction in joint care (activity pacing and joint projection), group discussion of exercise successes and barriers, group exercise, and scheduled individual consultations with the physical therapist (2 per participant, 15-20 minutes each) to address specific functional and therapeutic needs. Participants will also be given instructions for a home exercise program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individual Physical Therapy for Knee OA
Description: The individual PT arm, modeled after typical PT care for knee OA at the Durham VAMC and other health care settings, will include 2 1-hour visits with a physical therapist, 2-3 weeks apart. While the individual PT sessions will differ in structure from the group PT sessions they will include the same informational, assessment, and therapeutic content as the group sessions. Participants in this group will also be given instructions for the same home exercise program.
Study: NCT00901108

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabectome-IOL
Description: Trabectome removes an arc of trabecular meshwork and inner wall of Schlemm's canal to enhance aqueous outflow through natural drainage pathways.~Trabectome will be done first, followed by cataract surgery because Trabectome requires a clear view through the cornea using a goniolens, and this view may be compromised after cataract surgery.
Study: NCT01069354

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiesse® Injectable Dermal Filler with Lidocaine
Description: Calcium hydroxylapatite particles suspended in an aqueous-based gel carrier with 3% lidocaine hydrochloride (HCl)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiesse® Injectable Dermal Filler without Lidocaine
Description: Calcium hydroxylapatite particles suspended in an aqueous-based gel carrier without 3% lidocaine hydrochloride (HCl)
Study: NCT02392325

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN1Δ30
Description: Administered subcutaneously in 0.5 mL containing 10\^3.0 plaque-forming units (PFU)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered subcutaneously in 0.5 mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN2Δ30-7169
Description: Administered subcutaneously in 0.5 mL containing 10\^3.0 PFU

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN2Δ30-7169
Description: Administered subcutaneously in 0.5 mL containing 10\^3.0 PFU
Study: NCT01281202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vigabatrin
Description: Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Tablets
Study: NCT03346811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Patients with plasma EGFR mutation-positive are arranged to receive icotinib with a dose of 125 mg three times per day, till progressive disease or unaccepted toxicity
Study: NCT03536286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Encouragement
Description: Households will be visited and encouraged to enroll in Asili

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Encouragement
Description: Households will be visited and encouraged to enroll in Asili
Study: NCT00521703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: oral cavity and throat were sprayed with lidocaine 10% two to three puffs before propofol infusing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tannic acid
Description: oral cavity and throat were sprayed with placebo (tannic acid 0.5%) two to three puffs before propofol infusing
Study: NCT01494428

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rhBMP-2/ACS/allograft bone dowel
Description: The rhBMP-2/ACS will be used in conjunction with an allograft bone dowel.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous bone/allograft bone dowel
Description: An allograft bone dowel contains autogenous bone taken from the patient's iliac crest.
Study: NCT03172702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zirconium Cyclosilicate
Description: Correction Phase Dosing: Sodium Zirconium Cyclosilicate 10 g three times daily (TID) from 24 to 72 Extended Dosing: Sodium Zirconium Cyclosilicate 5 g once daily (QD). Sodium Zirconium Cyclosilicate dose increased or decreased in increments/decrements of 5 g QD up to a maximum of 15 g QD or a minimum of 5 g every other day (QOD) (or 2.5 g QD) based on i-STAT potassium measurements up to 12 months.
Study: NCT04304352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Metronomic Vinorelbine 40 mg orally thrice a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Metronomic Capecitabine 500 mg, thrice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Metronomic Cyclophosphamide 50 mg daily
Study: NCT03118921

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: The first session aims to present the virtual reality material that will be used. The second session will take place 2 weeks after the first session and will consist of the use of the immersion software.
Study: NCT01077544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Nilotinib capsules were delivered in bottles with dose strengths of 50mg, 150mg and 200mg.~Patients were administered nilotinib 230 mg/m2 (per BSA) bid, orally, rounded to the nearest 50 mg (max single dose 400 mg) for 28 days (1 cycle) for up to 12 cycles prior to protocol amendment 3 and up to 24 cycles post amendment 3. Capsules were to be swallowed whole with water. Apple sauce (puréed apple) may have been used as a vehicle for dosing where capsules were not able to be swallowed whole with water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Nilotinib capsules were delivered in bottles with dose strengths of 50mg, 150mg and 200mg.~Patients were administered nilotinib 230 mg/m2 (per BSA) bid, orally, rounded to the nearest 50 mg (max single dose 400 mg) for 28 days (1 cycle) for up to 12 cycles prior to protocol amendment 3 and up to 24 cycles post amendment 3. Capsules were to be swallowed whole with water. Apple sauce (puréed apple) may have been used as a vehicle for dosing where capsules were not able to be swallowed whole with water.
Study: NCT03320616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYP001a
Description: Oral EYP001a capsules - 100 mg strength

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYP001a
Description: Oral EYP001a capsules - 100 mg strength

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYP001a
Description: Oral EYP001a capsules - 100 mg strength

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYP001a
Description: Oral EYP001a capsules - 100 mg strength
Study: NCT00901108

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trab-IOL
Description: Trabeculectomy bypasses the normal aqueous outflow channels of the eye and creates an external filtration pathway (called a filtering bleb) for aqueous to drain and be reabsorbed back into the circulation. Mitomycin C is an agent used during this procedure to decrease scar formation around the new passage.~Cataract surgery will be done first, followed by Trabeculectomy with Mitomycin C.
Study: NCT04026529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: walking on incline or walking at increasing speed
Description: Subjects will be prepared for data collection by wearing a form-fitting suit (i.e., wrestling singlet) and obtaining height and body weight. Retro-reflective markers will be placed bilaterally on anatomical locations of the feet, legs, and hips.~Subjects will be outfitted with the portable metabolic cart and oximeter as in the previous visit. One of two treadmill trials will be performed: 1) at the speed and 2) at the slope +speed determined in the previous visit. Trial order will be randomized among subjects and across visits 3 \& 4. For each trial, subjects will be asked to walk on a treadmill for up to 6 minutes. Speed or slope will be increased every 30 seconds and they will be asked to walk for one minute at that speed or slope.
Study: NCT04723823

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor or sensory imagery with fMRI
Description: Brain activity will be measured using fMRI while participants imagine different movements or sensations in order to assess the organization of sensorimotor cortical activity after injury

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor or sensory imagery with fMRI
Description: Brain activity will be measured using fMRI while participants imagine different movements or sensations in order to assess the organization of sensorimotor cortical activity after injury
Study: NCT03574597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Subjects will start semaglutide treatment at 0.24 mg; dose will gradually be increased every 4 weeks up to 2.4 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (semaglutide)
Description: Placebo will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Participants will receive placebo at an equivalent dose to semaglutide.
Study: NCT02770781

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise regimen
Description: Subjects will receive a personal exercise regimen based on their health history and individual capability.
Study: NCT04237506

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted ballet dance
Description: The one-hour ballet dance class will be provided twice per week for six weeks. The syllabi are adapted from the Joffrey Ballet Academy and Royal Academy of Dancing that are targeting grades primary to level 1 and typically developing kids at the age of 6 to 10 years old. PI will be the class instructor, and the class structure will follow the guidelines in 'Dance program for physical rehabilitation and participation in children with cerebral palsy' by Lopez-Ortiz et al.
Study: NCT01868295

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleeping with denture
Description: Sleeping with denture at night
Study: NCT01011621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% prednisolone acetate cream
Description: Small amount applied over the lesion twice a day for 14 days.
Study: NCT01637922

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 201335
Description: BI 201335 for 9 days
Study: NCT01011621

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% betamethasone valerate cream
Description: Small amount applied over the lesion twice a day for 14 days.
Study: NCT01071564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma-Secretase Inhibitor RO4929097
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT01071564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Given PO
Study: NCT00528489

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PennVax B
Description: DNA vaccine containing the HIV genes Gag, Pol, and Env

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PennVax B
Description: DNA vaccine containing the HIV genes Gag, Pol, and Env

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PennVax B
Description: DNA vaccine containing the HIV genes Gag, Pol, and Env
Study: NCT05313178

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Bacillus Coagulans GBI-30, 6086
Description: In a randomized, double-blind, crossover fashion, study participants will supplement on a daily basis for two weeks during one study period with a 25-gram dose of either milk protein concentrate or a 25-gram dose of milk protein concentrate with bacillus coagulans GBI-30, 6086. Each dose will be ingested at the same time of day with 8 - 12 fluid ounces of cold tap water. All participants will be required to complete a supplementation log to document when each dose of their assigned protein is consumed. Upon completion of their first assigned study protocol period, participants will observe a three-week washout period by returning to their normal dietary intake and physical activity habits before beginning supplementation for the remaining study period.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bacillus Coagulans GBI-30, 6086
Description: In a randomized, double-blind, crossover fashion, study participants will supplement on a daily basis for two weeks during one study period with a 25-gram dose of either milk protein concentrate or a 25-gram dose of milk protein concentrate with bacillus coagulans GBI-30, 6086. Each dose will be ingested at the same time of day with 8 - 12 fluid ounces of cold tap water. All participants will be required to complete a supplementation log to document when each dose of their assigned protein is consumed. Upon completion of their first assigned study protocol period, participants will observe a three-week washout period by returning to their normal dietary intake and physical activity habits before beginning supplementation for the remaining study period.
Study: NCT04433884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation using a laryngoscope
Description: Patients will undergo intubation using 2 different types of laryngoscopes and their hemodynamic response would be recorded

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation using a laryngoscope
Description: Patients will undergo intubation using 2 different types of laryngoscopes and their hemodynamic response would be recorded
Study: NCT00528489

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PennVax B
Description: DNA vaccine containing the HIV genes Gag, Pol, and Env

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-12
Description: Cytokine injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-15
Description: Cytokine injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-15
Description: Cytokine injection
Study: NCT01017770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine
Description: Coformulated AQ+AS by Sanofi-Aventis has been pre-qualified by WHO in 2008. It is administered once daily for three consecutive days, and it is available in three different dosages (25mg/67.5mg; 50mg/135mg; 100mg/270mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Description: Artemether-lumefantrine by Novartis was the first fixed-dose ACT that was prequalified by WHO in April 2004. A 3-day, 6-dose regimen of AL is recommended for infants and children weighing 5-35 kg and adults weighing \> 35 kg.
Study: NCT02754310

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Variation of scenarios
Description: Three different scenarios of pediatric asthma exacerbations: a mild exacerbation, a moderate exacerbation, and a severe exacerbation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Repeated scenarios
Description: The same scenario of a moderate pediatric asthma exacerbation is repeated three times.
Study: NCT04468633

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Baerveldt 350 implant
Description: The Baerveldt implant is an FDA-approved silicone, non-valved implant.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ahmed ClearPath 350 implant
Description: The Ahmed ClearPath is a non-valved glaucoma drainage device.
Study: NCT03643705

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-component intervention
Description: 4 components as described

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General prevention education
Description: General education as described
Study: NCT01498445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Starting Dose: 100 mg by mouth once daily of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Starting Dose: 100 mg by mouth once daily of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Starting Dose: 100 mg by mouth once daily of a 28 day cycle.
Study: NCT00638222

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol and Placebo
Description: All enrolled participants were randomized to receive Carvedilol or Placebo in a 2-way crossover design. Each intervention was administered over 8 weeks before switching to the alternative intervention. The study was terminated early, and data were not unblinded so participants cannot be reported separately.
Study: NCT02423343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galunisertib
Description: Administered orally
Study: NCT04288596

Intervention type: OTHER
Intervention: Participants undergoing ACHD intervention
Description: Participants will receive standard of care for their ACHD intervention.
Study: NCT02213796

Intervention type: DRUG
Group type: OTHER
Intervention: Meropenem
Study: NCT03517852

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Human Intravital Microscopy
Description: Intravital microscopy (IVM) allows real-time, direct visualization of microscopic blood vessels and calculation of blood flow.
Study: NCT03781297

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Narrative Exposure Therapy
Description: Narrative Exposure Therapy attempts to place the trauma within a narrative of the person's life. Anecdotal evidence of using this approach in the homeless population is that constructing an autobiography helps to give meaning to their problems and provide the initial steps in constructing a core sense of belonging and identity. Six sessions of individual therapy allows for participants to work with a therapist one-on-one to position their experiences of trauma within their life story.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Narrative Exposure Therapy
Description: Narrative Exposure Therapy attempts to place the trauma within a narrative of the person's life. Anecdotal evidence of using this approach in the homeless population is that constructing an autobiography helps to give meaning to their problems and provide the initial steps in constructing a core sense of belonging and identity. Six sessions of individual therapy allows for participants to work with a therapist one-on-one to position their experiences of trauma within their life story.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Genealogical Services
Description: At the start of their involvement in the, study participants randomized to this group will be provided with the option to access services from a professional genealogist, to trace their family history. Participants will be made aware of the fact that new family information will be revealed through this process, and also be informed of the standard methods that will be used to extract this information which could involve research through publicly available historical records or voluntary DNA testing.
Study: NCT02863484

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: pealing of the outer layer of the cavernous sinus